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into mitogen-activated protein kinase inhibitor 
resistance of cerebral melanoma metastases
Nina Zila1,2,3, Andrea Bileck2, Besnik Muqaku2, Lukas Janker2, Ossia M. Eichhoff4, Phil F. Cheng4, 
Reinhard Dummer4, Mitchell P. Levesque4, Christopher Gerner2 and Verena Paulitschke1,4*
Abstract 
Background: MAP kinase inhibitor (MAPKi) therapy for BRAF mutated melanoma is characterized by high response 
rates but development of drug resistance within a median progression-free survival (PFS) of 9–12 months. Under-
standing mechanisms of resistance and identifying effective therapeutic alternatives is one of the most important 
scientific challenges in melanoma. Using proteomics, we want to specifically gain insight into the pathophysiological 
process of cerebral metastases.
Methods: Cerebral metastases from melanoma patients were initially analyzed by a LC–MS shotgun approach per-
formed on a QExactive HF hybrid quadrupole-orbitrap mass spectrometer. For further validation steps after bioinfor-
matics analysis, a targeted LC-QQQ-MS approach, as well as Western blot, immunohistochemistry and immunocyto-
chemistry was performed.
Results: In this pilot study, we were able to identify 5977 proteins by LC–MS analysis (data are available via 
ProteomeXchange with identifier PXD007592). Based on PFS, samples were classified into good responders 
(PFS ≥ 6 months) and poor responders (PFS ≤ 3 months). By evaluating these proteomic profiles according to gene 
ontology (GO) terms, KEGG pathways and gene set enrichment analysis (GSEA), we could characterize differences 
between the two distinct groups. We detected an EMT feature (up-regulation of N-cadherin) as classifier between 
the two groups, V-type proton ATPases, cell adhesion proteins and several transporter and exchanger proteins to be 
significantly up-regulated in poor responding patients, whereas good responders showed an immune activation, 
among other features. We identified class-discriminating proteins based on nearest shrunken centroids, validated and 
quantified this signature by a targeted approach and could correlate parts of this signature with resistance using the 
CPL/MUW proteome database and survival of patients by TCGA analysis. We further validated an EMT-like signature as 
a major discriminator between good and poor responders on primary melanoma cells derived from cerebral metas-
tases. Higher immune activity is demonstrated in patients with good response to MAPKi by immunohistochemical 
staining of biopsy samples of cerebral melanoma metastases.
Conclusions: Employing proteomic analysis, we confirmed known extra-cerebral resistance mechanisms in the 
cerebral metastases and further discovered possible brain specific mechanisms of drug efflux, which might serve as 
treatment targets or as predictive markers for these kinds of metastasis.
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Background
The incidence of melanoma is increasing rapidly world-
wide, including countries with historically low rates. 
This increase is occurring at a faster rate than with 
any other neoplasm [1]. Up to one-fifth of melanoma 
patients develop metastatic disease, which has mainly 
been treated by chemotherapy, achieving response 
rates between 10 and 30% [2]. After cancers of the lung 
and breast, melanoma is the third most common cause 
of central nervous system (CNS) metastases [3, 4]. In 
patients with newly diagnosed stage IV disease, brain 
metastases are present in 20% of cases [5] and among 
patients with documented brain involvement, these 
lesions contribute to death in up to 95% [6]. In 40–60% 
of all melanoma patients, mutational activation of BRAF 
V600E can be found, resulting in constitutive activa-
tion of the serine-threonine protein kinase BRAF and 
the Ras-RAF-MEK-ERK signaling pathway, also known 
as mitogen activated protein (MAP) kinase pathway [7]. 
Until 2011, standard treatment for patients with inopera-
ble metastatic melanoma was dacarbazine (DTIC) [8]. In 
August 2011, the US Agency of Food and Drug Admin-
istration (FDA) approved Vemurafenib, a BRAF inhibitor 
(BRAFi), for the treatment of metastatic or unresectable 
melanoma with BRAF V600E mutation. Brain metasta-
ses pose special challenges because of the poor associ-
ated prognosis [9]. They are a major cause of mortality 
in patients with advanced melanoma. However, relatively 
little was known about the intracranial effectiveness of 
selective inhibitors because patients with brain metas-
tases have historically been excluded from clinical trials 
[10]. Recently a few studies investigated BRAFi treatment 
for melanoma patients with brain metastasis [11–13]. An 
open-label pilot study assessed Vemurafenib therapy in 
patients with BRAF V600 mutation positive metastatic 
melanoma with non-resectable, previously treated brain 
metastases and concluded that Vemurafenib can safely be 
used for the therapy of advanced symptomatic melanoma 
with metastasis to the brain and can result in meaning-
ful tumor regression [11]. In more than 50% of these 
cases clinical response, up to a complete remission, were 
achieved by Vemurafenib. Systemic therapy revolution-
ized melanoma treatment but unfortunately high initial 
responses are followed by acquired drug resistance after 
a median time of only 6–8 months [14, 15]. About 15% 
of the patients treated with BRAFi do not achieve tumor 
regression, because of intrinsic (primary) mechanisms 
of resistance and most patients who respond to therapy 
ultimately develop mechanisms of acquired (secondary) 
resistance, leading to progressive disease [16]. Initial suc-
cess was made by BRAFi therapy, but due to the reacti-
vation of the MAPK signaling pathway, patients showed 
resistance to therapy. Therefore a combination therapy 
of BRAF and MEK inhibitors (MEKi) was implemented 
and improved the effectiveness of targeted therapy even 
further by improving median PFS [17, 18]. Unfortunately, 
resistance to therapy is still challenging and especially the 
high mortality of brain metastases poses a huge ongo-
ing clinical problem. It is questionable whether there 
are brain specific efflux transporters contributing to the 
resistance of intracranial metastases and where differ-
ences or similarities between visceral and cerebral metas-
tases can be found. The phenotype-switching model was 
first described in melanoma by Hoek et  al. [19, 20] and 
characterizes two transcriptional distinct melanoma cell 
populations, a proliferative and an invasive type. Mela-
noma cells are able to switch back and forth between 
these two phenotypes and therefore explain the hetero-
geneous nature of melanoma cells [21]. It accounts for 
disease progression and tumor heterogeneity, as well as 
aspects of resistance [22]. Proliferative melanoma cells 
have been shown to be more responsive to MAPK path-
way inhibition than invasive phenotype cells, indepen-
dently of their mutation status [23, 24]. On the other 
hand, proliferative melanoma cells have shown to change 
their phenotype from proliferative to invasive state in 
response to long-term treatment with targeted therapy 
(BRAFi and MEKi), which is associated with drug resist-
ance. The major role in phenotype switching and the 
transition from a proliferative to an invasive cell type 
and ultimately leading to metastasis is played by EMT-
like mechanisms [25]. Identifying critical switches in 
EMT processes and finding a way to block these, might 
serve as a strategy to prevent metastasis and to decrease 
therapeutic resistance. Especially, the down-regulation of 
E-cadherin, balanced by the increased expression of mes-
enchymal neural cadherin (N-cadherin), this, so called 
cadherin switch, alters cell adhesion [26, 27] and is con-
sidered to be a fundamental event in EMT, leading to a 
loss of cell–cell contact, increased invasive properties 
and typical morphological changes [21, 28, 29].
In this study we showed, by analyzing brain tissue 
samples of patients with low and high PFS in response 
to MAPKi treatment, distinct differences between the 
two groups, using proteome profiling by shotgun MS. 
We analyzed the data according to gene ontology (GO) 
terms, KEGG pathways and gene set enrichment analy-
sis (GSEA). We were further able to identify an EMT 
mechanism (up-regulation of N-cadherin), V-type proton 
ATPases, calcium ion binding proteins, eukaryotic trans-
lation initiation factors, cell adhesion proteins, several 
transporter and exchanger proteins in poor responding 
patients, whereas good responders showed an immune 
activation and involvement of extracellular matrix struc-
tural constituents, among other features. Based on near-
est shrunken centroids we furthermore detected the 
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most discriminating proteins between those two groups. 
We validated the EMT like signature using primary mela-
noma cells derived from cerebral metastases with dif-
ferent response based on the IC50 to BRAF and MEK 
inhibitors. To validate the discriminative signature we 
used the CPL/MUW proteome database [30]. By a subse-
quent targeted approach, we performed a quantification 
and validation step of this discriminative signature. Func-
tional analysis of the EMT signature was performed by 
inducing EMT in a primary melanoma cell culture. As a 
final step we validated our findings clinically by correlat-
ing our protein signature with survival over TCGA analy-
sis and immunohistochemical staining (for study design 
see Additional file 1: Fig. S1).
Methods
All experiments were carried out according to the Dec-
laration of Helsinki principles after approval by the eth-
ics committee (Swissethics, Kantonale Ethikkommission 
Zurich, vote number 2014-0425). Cerebral melanoma 
metastases (n = 25) originating from surgical excisions 
and autopsy specimens were selected based on the clini-
cal information and patients’ different progression-free 
survival (PFS) after MAPKi treatment. For subsequent 
data analysis patients with a PFS ≥ 6  months were clas-
sified as a good responder (n = 9) and showed low pro-
gression, whereas patients with a PFS ≤ 3  months were 
classified as a poor responder (n = 16) and showed fast 
progression in their disease. Further validation steps 
included melanoma cells derived from cerebral metasta-
ses (n = 5) and FFPE (formalin-fixed paraffin-embedded) 
cerebral melanoma metastases tissue samples (n = 23), 
corresponding to patients from the initial metasta-
ses cohort. A clinical table with age, gender, treatment, 
response distribution, PFS, mutational status, all num-
ber of samples, IC50 of the cell systems and the applied 
methods can be found as Additional file 2: Table S1.
LC–MS sample preparation
2–5  mg of each cryopreserved tissue sample and 
cell pellets from confluent 75  cm2 tissue culture 
flasks were homogenized in 100  μl sample buffer 
(7.5 M Urea, 1.5 M Thiourea, 0.1 M dithiothreitol (DTT), 
4%  3-[(3-Cholamidopropyl)dimethylammonio]-1-pro-
panesulfonate (CHAPS), 0.05%  Sodium dodecyl sulfate 
(SDS)) using ultrasound. Protein concentrations were 
determined according to Bradford et  al. [31]. For pro-
teome analysis we prepared in-solution digests using 
a variation of the FASP protocol [32], as previously 
described [33]. Of each lysate 20 µg protein was concen-
trated onto a 10  kDa MWCO filter (molecular weight 
cut-off filter; Pall Nanosep Centrifugal Devices with 
Omega Membrane, #OD010), which was prewashed with 
LC–MS grade water (Merck Chemicals and Life Science 
GesmbH, Vienna, Austria), by centrifugation at 14,000×g 
for 15  min to remove all particles smaller than 10  kDa. 
Samples containing proteins were then reduced with 
200 µl dithiothreitol (DTT) solution (5 mg/ml dissolved 
in 8  M guanidinium hydrochloride in 50  mM ammo-
nium bicarbonate buffer, pH  8) and incubated at 56  °C 
for 30 min. After centrifugation at 14,000×g for 10 min, 
a washing step with 50  mM ammonium bicarbonate 
buffer was performed. For alkylation 200  µl iodoaceta-
mide (IAA) solution (10  mg/ml in 8  M guanidinium 
hydrochloride in 50 mM ammonium bicarbonate buffer) 
was added and incubated at 30 °C for 30 min in the dark. 
After centrifugation at 14,000×g for 10 min, proteins on 
top of the filters were washed with 50 mM ammonium 
bicarbonate buffer. Afterwards, filters were placed in a 
new Eppendorf tube, and 100  µl of 50 mM ammonium 
bicarbonate buffer as well as 10  µl of protease solution 
(Promega Trypsin/Lys-C Mix, Mass Spec Grade, #V5073, 
0.1  µg/µl) were added, and incubated at 37  °C for 18  h. 
After digestion, peptide samples were cleaned up with 
C-18 spin columns (Thermo Fisher Scientific Pierce C18 
spin columns, #89870). Peptides were collected with 0.5% 
trifluoroacetic acid (TFA) and acidified to a final concen-
tration of 1% TFA. C-18 columns were prewashed two 
times with 500  µl acetonitrile (ACN) and equilibrated 
with 200 µl of 5% ACN and 0.5% TFA by centrifugation 
at 1500×g for 1  min. Eluted and acidified peptide sam-
ples were loaded onto prewashed and equilibrated spin 
columns. After centrifugation at 1500×g for 1  min, the 
flow-through was reloaded on the column to maximize 
peptide binding and again centrifuged. After a washing 
step with 5% ACN and 0.5% TFA, peptides were eluted 
twice with 40 µl 50% ACN and 0.1% TFA and once with 
40 µl 80% ACN and 0.1% TFA into a new Eppendorf tube. 
Digested peptide samples were finally dried at 40 °C using 
a centrifugal vacuum concentrator (miVac GeneVac Duo 
Concentrator) and stored at −  20  °C until further MS 
analyses were performed.
LC–MS/MS shotgun analysis
As described previously [33, 34], dried samples were 
reconstituted in 5  µl 30% formic acid (FA) containing 
10  fmol each of 4 synthetic standard peptides (allow-
ing us to monitor the quality of the chromatographic 
separation) and diluted with 40 µl mobile phase A (98% 
 H2O, 2% ACN, 0.1% FA). Of this solution 2.5  µl were 
injected into the Dionex Ultimate 3000 nano HPLC-
system (Thermo Fisher Scientific). Peptides were first 
concentrated on a 2  cm × 75  µm C18 Pepmap100 pre-
column (Thermo Fisher Scientific) at a flow rate of 
10  µl/min using mobile phase A. Afterwards, separa-
tion of the peptides was achieved by eluting them from 
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the pre-column to a 50 cm × 75 µm Pepap100 analytical 
column (Thermo Fisher Scientific) applying a flow rate 
of 300 nl/min and using a gradient of 8% to 40% mobile 
phase B (80% ACN, 20% H2O, 0.1% FA), over 190 min for 
the analysis of samples. The mass spectrometric analy-
sis, with a technical replicate for each of the 18 samples, 
was performed on a QExactive HF orbitrap mass spec-
trometer, equipped with a nanospray ion source (Thermo 
Fisher Scientific), coupled to the nano HPLC system. For 
detection, MS scans were performed in the range from 
m/z 400–1400 at a resolution of 60,000 (at m/z = 200). 
MS/MS scans were performed choosing a top 12 method; 
HCD fragmentation was applied at 27% normalized colli-
sion energy and analysis in the orbitrap at a resolution of 
15,000 (at m/z = 200).
LC–MS shotgun data analysis
Protein inference as well as label-free quantitative (LFQ) 
data analysis was performed using the open source soft-
ware MaxQuant 1.3.0.5 including the Andromeda search 
engine and the Perseus statistical analysis package [35, 
36], a commonly used workflow for processing and sta-
tistical assessment of shotgun proteomics data. Protein 
inference was achieved searching against homo sapiens 
in the SwissProt Database (version 01/2013 with 20,264 
entries) allowing a mass tolerance of 5 ppm for MS spec-
tra and 20 ppm for MS/MS spectra as well as a maximum 
of 2 missed cleavages. In addition, carbamidomethylation 
on cysteins was included as fixed modification whereas 
methionine oxidation as well as N-terminal protein 
acetylation was included as variable modifications. Fur-
thermore, search criteria included a minimum of two 
peptide identifications per protein, at least one of them 
unique, and the FDR calculation based on q-values per-
formed for both, peptide identification as well as protein 
inference, less than 0.01. Prior to statistical analysis, pro-
teins were filtered for reversed sequences, contaminants 
and a minimum of three independent identifications per 
protein. The mass spectrometry-based proteomics data 
have been deposited to the ProteomeXchange Consor-
tium via the PRIDE [37] partner repository with the data-
set identifier PXD007592 and https://doi.org/10.6019/
pxd007592. Label-free quantification resulted in LFQ 
values for each individual protein and was used for quan-
titative assessment of protein regulation. For all samples 
the same initial protein amount of 20  µg was used and 
served for normalization. Using the Perseus statistical 
analysis package, differences of LFQ values were calcu-
lated. By applying a two-sided t test with p < 0.05 and an 
FDR-based permutation correction, significantly up- and 
down-regulated proteins with a minimum of a twofold 
abundance difference  (log2 fold change) were determined. 
All proteins meeting these criteria were considered in the 
present study. Subsequent annotation enrichment analy-
sis was performed based on gene ontology terms biologi-
cal process, cellular component and molecular function 
using DAVID (DAVID Bioinformatics Resources 6.7, 
National Institute of Allergy and Infectious Diseases) [38, 
39]. Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways according to Geiger et al. [40] were visualized 
using Pathview package of R [41]. The expression of pro-
teins was also analyzed for significantly enriched protein 
sets using Gene Set Enrichment Analysis (GSEA) [42]. 
Process using the GSEA software with the parameters 
set to ranking according to log fold change, minimum 
gene set size 15, maximum gene set size 500. To identify 
a potential biomarker profile, a classifier based on near-
est shrunken centroids was constructed using ClaNC and 
R [43]. Priors were chosen according to the number of 
samples. The performance of the classifier was tested by 
leaving-one-out cross validation.
Targeted LC–MS analysis
MRM method was developed based on shotgun data and 
using Skyline software (v.4.1) [44], as described recently 
[45]. Targeted MRM analysis was conducted on an Agi-
lent 6490 triple quadrupole mass spectrometer coupled 
with a nano-Chip-LC Agilent Infinity Series HPLC1290 
system. Peptides were separated by applying 19 min gra-
dient from 8 to 30% acetonitrile. The statistical analysis 
of MRM data was performed with MSstats (v.2.3.5) [46].
Cell culture
Melanoma cell cultures were established from surplus 
cerebral melanoma metastases after having obtained 
written, informed consent approved by the local IRB 
(EK647 and EK800). Cells were grown in RPMI (Sigma 
RPMI-1640, #R0883) supplemented with 5  mM  l-glu-
tamine (gibco l-glutamine, #25030), 1  mM sodium 
pyruvate (Sigma sodium pyruvate, #S8636) and 10% FBS 
(PAN biotech FBS Premium heat inactivated, #P30-1902, 
Aidenbach, Germany). Culture medium was changed 
every 2–3 days to ensure optimum conditions of growth, 
using aseptic techniques and a laminar flow bench. Cells 
were tested for mycoplasma contamination (Invivogen 
PlasmoTest Mycoplasma Detection Kit, #rep-pt) prior to 
their use for the described techniques.
Viability assay
Melanoma cells were seeded into 96-well plates in a den-
sity of 1.5 × 103 cells per well. After 24 h cells were treated 
with Raf inhibitors Encorafenib (Selleckchem LGX818, 
#S7108) or Vemurafenib (Selleckchem PLX4032, RG7204, 
#S1267) and MEK inhibitor Binimetinib (Selleckchem 
MEK162, ARRY-162, ARRY-438162, #S7007) in differ-
ent concentrations and incubated for 72 h. Proliferation 
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and viability of the cells was determined with a stand-
ard colorimetric assay using 7-hydroxy-3H-phenoxazin-
3-one-10-oxide sodium salt (Sigma Resazurin sodium 
salt, #R7017), where the bioreduction of the dye was 
measured at 595  nm. IC50 values were determined by 
nonlinear regression using the dose–response equations 
built into GraphPad Prism software version 5 (GraphPad 
Software Inc., USA).
Western blot
Patient derived melanoma cells were washed twice with 
cold PBS (gibco PBS, pH 7.4 (1X) without calcium or 
magnesium, #10010) and lysed with RIPA cell lysis buffer 
(20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA 
1% Triton-X 100, 1  mM  Na3VO4, 1X protease inhibitor 
cocktail (Roche cOmplete ULTRA Tablets, Mini, EASY-
pack, #05 892 970 001), 1X phosphatase inhibitor cock-
tail (Roche PhosSTOP EASYpack, #05 906 837 001)). 
Total protein content was quantified using a colorimetric 
assay (Bio-Rad DC Protein Assay, #5000112) according to 
the manufacturer’s protocol with bovine serum albumin 
(BSA) as standard. SDS–polyacrylamide gels were hand 
casted with 8% separating gel and for each sample 5 µg of 
total protein was loaded and separated by electrophoresis 
for 150 min by applying 100 V (using Bio-Rad Mini-Pro-
tean Tetra Cell). Using a semi-dry transfer unit (Hoefer 
TE70X semi-dry blotter) proteins were blotted onto a 
nitrocellulose membrane (Bio-Rad Nitrocellulose mem-
brane 0.45  µm, #162-0115) for 90  min at 70  mA. After 
a blocking step for 1  h at room temperature with 5% 
milk (Bio-Rad nonfat dry milk Blotting-Grade Blocker, 
#1706404) in TBS-T under agitation, the primary anti-
body (Cell Signaling E-Cadherin (24E10) Rabbit mAb, 
#3195; Cell Signaling N-Cadherin (D4R1H) XP Rabbit 
mAb, #13116) diluted 1:1000 in TBS-T was incubated 
overnight at 4  °C. After a washing step, the secondary 
antibody (Amersham ECL Peroxidase labelled anti-rab-
bit antibody, #NA934) was diluted 1:2000 in 5% milk in 
TBS-T and incubated under agitation for 1  h at room 
temperature. After a washing step bound antibodies were 
detected with enhanced chemiluminescence horseradish 
peroxidase (Thermo Fisher Scientific SuperSignal West 
Pico Chemiluminescent Substrate, #34080) in the dark 
room.
Immunohistochemical staining
Cerebral melanoma metastases tissue used for immu-
nohistochemistry was fixed in 4% formaldehyde solu-
tion and embedded in paraffin. The 4 µm sections were 
then deparaffinized in xylene and rehydrated. Epitope 
retrieval was performed in antibody specific buffers (Agi-
lent Dako Target Retrieval Solution, pH9). Staining was 
performed on an immunohistochemistry stainer (Agilent 
Dako Autostainer Link 48) using a labeled streptavidin–
biotin method visualized by AEC as chromogen (Agilent 
Dako REAL Detection System, Peroxidase/AEC, Rabbit/
Mouse, #K5003). The antibodies used were: CD3 (Dako 
Monoclonal Mouse Anti-Human CD3 Clone F7.2.38, 
#M7254; 1:50); CD4 (Dako Monoclonal Mouse Anti-
Human CD4 Clone 4B12, #M7310; 1:80); CD8 (Biocare 
Medical CD8 [C8/144B], #ACI3160A; 1:300). All slides 
were counterstained with hematoxylin (Agilent Dako 
REAL Hematoxylin, #S2020).
Immunocytochemical staining
Melanoma cell lines from cerebral metastases were taken 
out of cell culture and fixated with 7.5% formaldehyde 
solution. After two washing steps with PBS cells were 
concentrated onto glass slides using a cytospin centri-
fuge. Immunocytochemical staining was performed 
using a biotin-free detection system with horserad-
ish peroxidase polymer and AEC chromogen (Thermo 
Fisher Scientific Lab Vision UltraVision LP Detection 
System, #TL-015-HA). The antibodies used (Cell Signal-
ing E-Cadherin (24E10) Rabbit mAb, #3195; Cell Signal-
ing N-Cadherin (D4R1H) XP Rabbit mAb, #13116) were 
diluted 1:1000 in 1% BSA in PBS and incubated overnight 
at 4  °C. After chromogenic development all slides were 
counterstained with hematoxylin (Merck Papanicolaou’s 
solution 1a Harris’ hematoxylin, #109253).
TGFβ treatment, RNA extraction and microarray data 
analysis
The BRAFV600E mutated primary human melanoma cell 
line M000921 has been established from surplus material 
from cutaneous melanoma metastases. This cell line has 
been previously characterized as a proliferative-pheno-
type melanoma culture (by means of melanoma pheno-
type-switching model) and shared with multiple studies 
and international laboratories [24, 47–50]. Expression 
data from a Affymetrix HG-U133 plus 2.0 oligonucleo-
tide microarray is deposited on GEO (GSM700745). 
Written informed consent was approved by the local IRB 
(EK647 and EK800). Clinical diagnosis was confirmed 
by histology and immunohistochemistry. Melanoma cell 
culture was grown in RPMI (Sigma RPMI-1640, #R0883) 
including 5  mM  l-glutamine (gibco l-glutamine, 
#25030), 1  mM sodium pyruvate (Sigma sodium pyru-
vate, #S8636) and 10% FBS (PAN biotech FBS Premium 
heat inactivated, #P30-1902, Aidenbach, Germany). 
M000921 melanoma cells were kept in medium contain-
ing 5  ng/ml human recombinant TGFβ (R&D Systems, 
#240-B) for a period of 12  days. Medium containing 
fresh TGFβ protein was changed every 3 days. RNA was 
extracted from both untreated and TGFβ treated cell cul-
ture using TRIzol reagent (Invitrogen, USA) following 
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manufacturer’s protocol. RNA labelling, hybridization 
to microarray (HG-U133 plus 2.0, Affymetrix) and data 
were statistically analyzed as described previously [49].
TCGA data
Gene expression and clinical information were derived 
from The Cancer Genome Atlas (TCGA, cutaneous mel-
anoma dataset (n = 456)) [51]. Briefly, patients were seg-
regated according to the upper and lower quartile of gene 
expression and significant differences in survival rates are 
evaluated with the log-rank statistical test (p value < 0.05). 
The survival curves were visualized by Kaplan–meier 
plots.
Results
Proteome profiling of cerebral melanoma metastases
In this study we generated proteome profiling data out of 
cerebral melanoma metastases by shotgun proteomics. 
As a result, a total of 5977 proteins were detected in the 
tissue samples, assembled from 49,501 distinct peptides, 
were identified and assessed using a label-free quantifi-
cation approach. Like previously described, the shotgun 
proteomic strategy has a unique potential to discover 
novel functional aspects of proteins and to determine 
relative abundance levels of proteins identified in differ-
ent samples [52]. For our comparison we assigned the 
samples to two groups based on patients’ PFS. For further 
evaluation, all proteins with p < 0.05 and fold change dif-
ferences ≥ 2.0 (student t-test difference) were taken into 
consideration. This corresponded to 1636 proteins more 
abundant in the poor responder group (patients with 
PFS ≤ 3 months) and 271 proteins in the good responder 
group (patients with PFS ≥ 6 months).
Functional discrimination of the subgroups
For a functional discrimination between good and poor 
responder we used gene ontology (GO) annotations 
(Fig.  1). In order to gain a better understanding on the 
molecular interaction and connection of the individual 
candidates we mapped differentially regulated proteins 
to functional KEGG (Kyoto Encyclopedia of Genes 
and Genomes) pathways (Fig.  2). Furthermore, Gene 
Set Enrichment Analysis (GSEA) [42] was applied and 
showed very similar results (see Additional file 3: Fig. S2 
for enriched pathways and Additional file 4: Table S2 for 
GSEA statistics). By both methods, we could show that 
cell adhesion molecules, calcium signaling pathway and 
MAPK signaling pathway proteins were overrepresented 
in poor responders, while complement and coagula-
tion cascade proteins were overrepresented in good 
responders.
We identified significant differentially expressed pro-
tein groups between the good (with higher PFS) and poor 
(with lower PFS), shown in the volcano plot (Fig. 3).
Identification of proteins involved in the MAPK signal-
ing pathway, V-type proton ATPases, calcium ion bind-
ing proteins, eukaryotic translation initiation factors, 
proteins involved in cell adhesion, neuronal proteins, 
transporter and exchanger proteins were significantly 
up-regulated in the poor responder group compared to 
the good responder group. Samples from patients who 
responded poorly to MAPKi treatment also showed a 
significant higher expression of Cadherin-2 (CDH2), also 
known as N-Cadherin.
Whereas patients who responded well to MAPKi 
showed a strong immunogenic signature, as well as pro-
teins associated with the extracellular matrix (ECM), a 
subgroup of cell adhesion proteins, which are involved 
in immunological responses and apolipoproteins were 
found to be elevated amongst this subgroup. Individual 
proteins can be found in Tables 1 and 2.
Identification of discriminative proteins
To generalize our proteomic findings and enable the 
translation of the results towards clinical application, we 
constructed a classifier based on nearest shrunken cen-
troids to identify a potential biomarker profile. We were 
able to identify 9 proteins that are needed to discriminate 
between good and poor responders shown in Table 3 and 
illustrated in Fig. 4.
EMT feature as a major classifier between good and poor 
prognosis validated in primary melanoma cell cultures
With the LC–MS shotgun approach we could show that 
samples from patients who responded poorly to MAPKi 
treatment showed a significantly higher expression of 
Cadherin-2 (CDH2), also known as N-Cadherin. For 
independent validation, we performed immunocyto-
chemistry on primary melanoma cell cultures derived 
from cerebral melanoma metastases and Western blot on 
the lysates of these cells with E- and N-cadherin antibod-
ies. The melanoma cells are classified as either sensitive 
(n = 3) or resistant (n = 2) based on the IC50 values for 
the BRAF/MEK inhibitors as determined by a viability 
assay. By these experiments we could show that the sen-
sitive cells are E-cadherin positive, whereas the resistant 
cells were N-cadherin positive. This data strongly sug-
gests EMT as a major classifier between good and poor 
prognosis (Fig. 5).
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Validation of discriminative signature by CPL/MUW 
proteome database
To further assess the discriminative signature (Table  3, 
Fig.  4) on protein level we tested the candidates using 
CPL/MUW proteome database [30], including 255 cell 
cultures, cell states and tissue, leading to a high protein 
similarity (57.14%) to the resistant melanoma cell line 
TMFI [30, 53]. In addition, we found one protein of our 
Fig. 1 Gene annotation enrichment analysis using the concept of GO annotations for poor responder (left column) and good responder (right 
column). Classification by the GO term biological process (BP) shows pathways and larger processes made up of the activities of multiple gene 
products, classification by the GO term cellular component (CC) shows where gene products are active and classification by the GO term molecular 
function (MF) shows molecular activities of gene products. Fold enrichment values for individual GO terms, count (genes involved in the term), p 
value and FDR (false discovery rate, calculated using the Benjamini–Hochberg procedure), listed next to the graph, were calculated using DAVID 
bioinformatics resources
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Fig. 2 KEGG pathway visualization of the coagulation and complement cascades (a), cell adhesion molecules (b), calcium signaling pathway (c) 
and MAPK signaling pathway (d). Red: up-regulated in good responder; blue: down-regulated in good responder
Fig. 3 Regulation of proteins in patients with poor and good response. The volcano plot shows the difference in the LFQ values (fold change, 
logarithmic scale to the base of two) on the x-axis including their corresponding p values (logarithmic scale) on the y-axis. Extended information on 
the proteins can be found in Tables 1 and 2
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Table 1 Proteins significantly up-regulated in poor responder patients as indicated in the volcano plot
Acc. Nr. Protein name Gene name log2 fold change (t-test difference) p value t-test significant
Eukaryotic translation initiation factors (EIFs)
Q14232 Translation initiation factor eIF-2B subunit alpha EIF2B1 1.04 2.48E − 03
Q14152 Eukaryotic translation initiation factor 3 subunit A EIF3A 1.13 5.71E − 03
P55884 Eukaryotic translation initiation factor 3 subunit B EIF3B 1.57 3.62E − 03
O00303 Eukaryotic translation initiation factor 3 subunit F EIF3F 1.23 9.41E − 03
O75821 Eukaryotic translation initiation factor 3 subunit G EIF3G 1.59 4.81E − 02
Q13347 Eukaryotic translation initiation factor 3 subunit I EIF3I 2.88 4.29E − 05 *
Q9UBQ5 Eukaryotic translation initiation factor 3 subunit K EIF3 K 1.85 3.50E − 05
Q9Y262 Eukaryotic translation initiation factor 3 subunit L EIF3L 1.57 7.30E − 03
P23588 Eukaryotic translation initiation factor 4B EIF4B 1.69 1.44E − 03
Q15056 Eukaryotic translation initiation factor 4H EIF4H 1.68 3.92E − 04
O60841 Eukaryotic translation initiation factor 5B EIF5B 1.26 2.53E − 02
Neuronal proteins
Q8N111 Cell cycle exit and neuronal differentiation protein 1 CEND1 2.86 1.98E − 03
P51674 Neuronal membrane glycoprotein M6-a GPM6A 5.30 5.24E − 05 *
P62166 Neuronal calcium sensor 1 NCS1 3.55 6.65E − 05 *
Q7Z3B1 Neuronal growth regulator 1 NEGR1 3.71 1.93E − 03
Q15818 Neuronal pentraxin-1 NPTX1 3.07 4.79E − 03
Q92823 Neuronal cell adhesion molecule NRCAM 2.44 3.48E − 03
Q9UH03 Neuronal-specific septin-3 SEPT3 3.40 3.68E − 04
P17600 Synapsin-1 SYN1 4.68 2.47E − 04 *
Q92777 Synapsin-2 SYN2 5.49 3.17E − 04 *
O14994 Synapsin-3 SYN3 2.46 5.70E − 03
Transporter proteins
P30531 Sodium- and chloride-dependent GABA transporter 1 SLC6A1 3.44 8.85E − 06 *
P43003 Excitatory amino acid transporter 1 SLC1A3 3.17 2.51E − 03
P43004 Excitatory amino acid transporter 2 SLC1A2 4.98 5.16E − 03
P43007 Neutral amino acid transporter A SLC1A4 1.81 4.10E − 02
P48066 Sodium- and chloride-dependent GABA transporter 3 SLC6A11 2.12 4.95E − 04
Q15043 Zinc transporter ZIP14 SLC39A14 1.28 3.30E − 03
Q6PML9 Zinc transporter 9 SLC30A9 1.57 1.36E − 02
Q8N4V1 Membrane magnesium transporter 1 MMGT1 1.19 3.22E − 02
Q8TBB6 Probable cationic amino acid transporter SLC7A14 1.78 6.86E − 03
Q96QE2 Proton myo-inositol cotransporter SLC2A13 2.68 1.94E − 06 *
Q99726 Zinc transporter 3 SLC30A3 2.03 2.95E − 02
Q9H1V8 Sodium-dependent neutral amino acid transporter 
SLC6A17
SLC6A17 2.51 1.39E − 02
Q9NS82 Asc-type amino acid transporter 1 SLC7A10 1.44 6.39E − 03
Exchanger proteins
P32418 Sodium/calcium exchanger 1 SLC8A1 1.66 4.06E − 02
Q8TCU6 Phosphatidylinositol 3,4,5-trisphosphate-dependent 
Rac exchanger 1 protein
PREX1 1.03 1.03E − 03
Q92581 Sodium/hydrogen exchanger 6 SLC9A6 1.76 9.73E − 03
Q9UPR5 Sodium/calcium exchanger 2 SLC8A2 4.39 1.18E − 03
V-type proton ATPases
Q15904 V-type proton ATPase subunit S1 ATP6AP1 1.41 3.12E − 02
Q93050 V-type proton ATPase 116 kDa subunit a isoform 1 ATP6V0A1 2.57 2.75E − 04
P27449 V-type proton ATPase 16 kDa proteolipid subunit ATP6V0C 2.36 5.37E − 03
P61421 V-type proton ATPase subunit d 1 ATP6V0D1 3.96 8.92E − 07 *
P38606 V-type proton ATPase catalytic subunit A ATP6V1A 1.82 6.37E − 05
Page 10 of 22Zila et al. Clin Proteom  (2018) 15:13 
The table shows UniProt accession number (Acc. Nr.), protein name, gene name, t-test difference between LFQ values of poor and good responding patients (fold 
change, logarithmic scale to the base of two) with corresponding p values and t-test significance (rows with a t-test result above s0 = 0.5 and FDR 0.01 are reported as 
significant)
Table 1 continued
Acc. Nr. Protein name Gene name log2 fold change (t-test difference) p value t-test significant
P21281 V-type proton ATPase subunit B, brain isoform ATP6V1B2 1.62 2.37E − 04
P21283 V-type proton ATPase subunit C 1 ATP6V1C1 1.51 5.27E − 05
Q9Y5K8 V-type proton ATPase subunit D ATP6V1D 2.19 5.15E − 04
P36543 V-type proton ATPase subunit E 1 ATP6V1E1 1.27 6.60E − 04
Q16864 V-type proton ATPase subunit F ATP6V1F 3.12 5.47E − 07 *
O75348 V-type proton ATPase subunit G 1 ATP6V1G1 2.39 5.16E − 04
O95670 V-type proton ATPase subunit G 2 ATP6V1G2 1.40 4.11E − 04
Q9UI12 V-type proton ATPase subunit H ATP6V1H 2.75 4.83E − 04
MAP-kinases
P28482 Mitogen-activated protein kinase 1 MAPK1 1.78 6.70E − 04
P53779 Mitogen-activated protein kinase 10 MAPK10 2.27 1.27E − 03
P27361 Mitogen-activated protein kinase 3 MAPK3 1.79 1.39E − 03
Q9UPT6 C-Jun-amino-terminal kinase-interacting protein 3 MAPK8IP3 2.21 1.83E − 03
Cell adhesion proteins
O00533 Neural cell adhesion molecule L1-like protein CHL1 1.59 3.85E − 02
O15394 Neural cell adhesion molecule 2 NCAM2 2.56 1.84E − 02
P13591 Neural cell adhesion molecule 1 NCAM1 3.72 1.12E − 04 *
P32004 Neural cell adhesion molecule L1 L1CAM 4.27 1.91E − 06 *
Q14982 Opioid-binding protein/cell adhesion molecule OPCML 4.53 7.99E − 04 *
Q14CZ8 Hepatocyte cell adhesion molecule HEPACAM 2.49 1.23E − 02
Q8N3J6 Cell adhesion molecule 2 CADM2 4.32 1.24E − 03
Q8NFZ8 Cell adhesion molecule 4 CADM4 1.74 2.53E − 02
Q92823 Neuronal cell adhesion molecule NRCAM 2.44 3.48E − 03
Calcium-ion binding proteins
P62158 Calmodulin CALM1 1.36 9.22E − 06
Q14012 Calcium/calmodulin-dependent protein kinase type 1 CAMK1 2.17 4.56E − 04
Q9UQM7 Calcium/calmodulin-dependent protein kinase type 
II subunit alpha
CAMK2A 3.00 5.85E − 04
Q13554 Calcium/calmodulin-dependent protein kinase type 
II subunit beta
CAMK2B 3.98 2.08E − 03
Q13555 Calcium/calmodulin-dependent protein kinase type II 
subunit gamma
CAMK2G 2.77 5.24E − 03
Q16566 Calcium/calmodulin-dependent protein kinase type 
IV
CAMK4 1.98 1.25E − 02
Q8N5S9 Calcium/calmodulin-dependent protein kinase kinase 
1
CAMKK1 2.13 8.09E − 03
Q96RR4 Calcium/calmodulin-dependent protein kinase kinase 
2
CAMKK2 2.03 8.67E − 03
Q9P1Y5 Calmodulin-regulated spectrin-associated protein 3 CAMSAP3 2.35 8.13E − 03
P54750 Calcium/calmodulin-dependent 3,5-cyclic nucleotide 
phosphodiesterase 1A
PDE1A 1.97 5.00E − 03
Q01064 Calcium/calmodulin-dependent 3,5-cyclic nucleotide 
phosphodiesterase 1B
PDE1B 2.54 1.25E − 02
EMT
P19022 Cadherin-2 CDH2 2.53 1.02E − 03
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Table 2 Proteins significantly up-regulated in good responder patients as indicated in the volcano plot
The table shows UniProt accession number (Acc. Nr.), protein name, gene name, t-test difference between LFQ values of poor and good responding patients (fold 
change, logarithmic scale to the base of two) with corresponding p values and t-test significance (rows with a t-test result above s0 = 0.5 and FDR 0.01 are reported as 
significant)
Acc. Nr. Protein name Gene name log2 fold change (t-test difference) p value t-test significant
Immune response related proteins
P05164 Myeloperoxidase MPO 4.53 1.69E − 05 *
P01909 HLA class II histocompatibility antigen, DQ alpha 1 
chain
HLA-DQA1 1.43 1.01E − 03
P04233 HLA class II histocompatibility antigen gamma chain CD74 1.74 7.47E − 03
P20039 HLA class II histocompatibility antigen, DRB1-11 beta 
chain
HLA-DRB1 2.99 2.46E − 03
Q95365 HLA class I histocompatibility antigen, B-38 alpha chain HLA-B 1.84 3.64E − 03
Q5Y7A7 HLA class II histocompatibility antigen, DRB1-13 beta 
chain
HLA-DRB1 1.38 1.70E − 03
P01594 Ig kappa chain V-I region AU 1.07 7.46E − 03
P01609 Ig kappa chain V-I region Scw 1.58 2.02E − 03
P01613 Ig kappa chain V-I region Ni 1.86 1.68E − 02
P01617 Ig kappa chain V-II region TEW 1.61 4.60E − 03
P01623 Ig kappa chain V-III region WOL 1.89 1.87E − 03
P01777 Ig heavy chain V-III region TEI 1.78 1.97E − 03
P01767 Ig heavy chain V-III region BUT 1.46 3.39E − 02
P01779 Ig heavy chain V-III region TUR 2.24 9.82E − 04
P01834 Ig kappa chain C region IGKC 1.56 4.17E − 03
P01857 Ig gamma-1 chain C region IGHG1 1.40 9.49E − 03
P01860 Ig gamma-3 chain C region IGHG3 1.42 1.01E − 02
P01871 Ig mu chain C region IGHM 2.24 7.25E − 03
P01876 Ig alpha-1 chain C region IGHA1 1.12 5.26E − 02
P01880 Ig delta chain C region IGHD 1.36 4.04E − 02
Apolipoproteins
O14791 Apolipoprotein L1 APOL1 1.82 1.43E − 03
P02647 Apolipoprotein A-I APOA1 1.94 2.86E − 04
P04114 Apolipoprotein B-100 APOB 3.55 1.17E − 03
P06727 Apolipoprotein A-IV APOA4 5.06 2.61E − 06 *
Cell adhesion (in immune response)
P16284 Platelet endothelial cell adhesion molecule PECAM1 1.48 5.04E − 02
P31997 Carcinoembryonic antigen-related cell adhesion 
molecule 8
CEACAM8 1.86 3.08E − 03
P40199 Carcinoembryonic antigen-related cell adhesion 
molecule 6
CEACAM6 1.16 3.99E − 02
Extracellular matrix (ECM) components
P02452 Collagen alpha-1(I) chain COL1A1 3.67 2.18E − 02
P02751 Fibronectin FN1 2.61 4.26E − 03
P08123 Collagen alpha-2(I) chain COL1A2 3.24 1.25E − 02
P25067 Collagen alpha-2(VIII) chain COL8A2 1.29 9.84E − 03
P39059 Collagen alpha-1(XV) chain COL15A1 1.48 4.46E − 02
Q05707 Collagen alpha-1(XIV) chain COL14A1 2.53 5.55E − 02
Q96P44 Collagen alpha-1(XXI) chain COL21A1 1.78 3.42E − 02
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signature exclusively in TMFI, supporting our observa-
tion that this set of proteins is apparently characteristic 
for resistance (Additional file 5: Fig. S3).
Validation and quantification of discriminative proteins 
by a targeted LC–MS analysis
Furthermore, we validated and quantified the discrimi-
native protein signature (Table 3, Fig. 4) with a targeted 
MS approach. We were able to validate our previous find-
ings by the shotgun MS screen demonstrating significant 
protein expression between the groups of good and poor 
responding patients (Fig. 6).
EMT-like signature induced by TGFβ can be correlated 
to the signature of poor responder
TGFβ-induced epithelial-to-mesenchymal-like transition 
(EMT-like) has been described in melanoma recently 
[25] and is characterized by melanoma cells switching 
from a proliferative phenotype to an invasive pheno-
type which is accompanied by induced drug-resistance 
to BRAF and MEK inhibitor treatment [24, 54]. Here we 
have correlated genes upregulated by TGFβ (EMT genes) 
to proteins up-regulated in brain metastasis of melanoma 
patients treated with BRAF and MEK inhibitors (see 
Fig. 7 for functional annotation categories (DAVID Bio-
informatics Resources 6.7, National Institute of Allergy 
and Infectious Diseases) and Additional file 6: Table 3 for 
full list of overlapping data between TGFβ induced sig-
nature in microarray data and shotgun proteomics data 
in cerebral melanoma metastases). Correlation of fac-
tors regulated in TGFβ induced EMT with the proteome 
signature of the patients that showed poor response was 
significant.
Correlation of the resistance signature to patient survival
To demonstrate clinical relevance of the protein signa-
ture we researched the melanoma dataset (n = 456) of 
The Cancer Genome Atlas (TCGA) [51] and were able 
to show that three candidates, DDB1- and CUL4-associ-
ated factor 7, Ubiquitin-conjugating enzyme E2 Q1 and 
Anamorsin, out of the 9 discriminative proteins correlate 
with patients’ survival (Fig. 8).
Increased immune cell presence in the cerebral metastases 
of good responder
The proteome signature of good responders was defined 
also by the up-regulation of immunogenic markers 
which we confirmed by immunohistochemical stain-
ing on the different T cell populations (CD3, CD4, CD8) 
on the FFPE cohort of clinical samples. These samples 
were classified as either good responder (n = 7) or poor 
responder (n = 15) based on PFS. The stained slides were 
evaluated by a dermatopathologist. Here we were able to 
demonstrate that poor response is characterized by less 
immune cell infiltrate in melanoma brain metastases, 
confirming our observation of higher immunological 
potential in the good responder (Fig. 9).
Discussion
In this study design we used a five-step approach from 
MS proteome analysis up to clinical validation of patient 
samples in order to describe two distinct protein expres-
sion signatures defining treatment outcome to MAPK 
inhibition of patients with metastatic melanoma to the 
brain. Starting with shotgun MS to identify differen-
tially expressed proteins between a set of good and poor 
responders with brain metastasis to targeted therapy. 
Next a variety of pathway analysis tools, GO terms, 
KEGG pathways, and GSEA, to define a set of biological 
and signaling pathways to distinguish between the good 
and poor responders. In step three we applied the near-
est shrunken centroid classifier method and were able to 
define a 9 protein signature. Discriminative proteins were 
validated in step four by CPL/MUW proteome database 
and an EMT signature in vitro in melanoma cells derived 
from brain metastasis resistant to MAPK inhibition. Our 
next step was further validation and also quantification 
over a targeted MS approach. This was followed by a 
functional validation of the EMT signature. Finally, in the 
last step we also showed clinical validation by correlating 
survival of patients with the resistant signature and per-
formed immunohistochemistry on cerebral melanoma 
metastases. Employing proteomic analysis, we confirmed 
known extra-cerebral resistance mechanisms in cerebral 
metastases and further uncovered possible brain specific 
mechanisms of drug efflux, which might serve as treat-
ment targets or as predictive markers for these kinds of 
metastases.
After our initial screen using shotgun LC–MS, we 
investigated pathways differing most apparently between 
good and poor responders. The MAPK signaling pathway 
was most reassuring since it represents one of the main 
resistance mechanisms known in melanoma [55].
We then searched for protein candidates, which played 
a role in these pathways and performed literature search 
in order to investigate whether these markers play a role 
in resistance mechanisms (Fig. 3).
V-type proteins, a group of proton ATPases, are signifi-
cantly up-regulated in poor responders. V-type proton 
ATPases transport hydrogen ions (H+) across mem-
branes, which may cause an acidic environment and thus 
lead to inactivation of T cells [56, 57]. This might support 
the hypothesis that resistance is supported by inactivat-
ing immune cells. V-type proteins might also be involved 
in drug efflux; their role in acidifying the ECM and thus 
Page 14 of 22Zila et al. Clin Proteom  (2018) 15:13 
maintaining multi-drug-resistance (MDR) properties has 
already been shown [58].
Eukaryotic translation initiation factors (EIFs) are 
pivotal in cancer progression and involved in different 
hallmarks of cancer [59, 60]. Complexes of this group 
of proteins have been shown to function as a nexus of 
resistance to anti-BRAF and anti-MEK cancer therapies 
[61] and were also found up-regulated in the samples of 
patients with poor response to MAPKi treatment.
The overrepresentation of a large group of neuronal 
proteins (Table  1) matches with their suspected role in 
cell migration and metastasis. Here, where the move-
ment of cells is controlled, similar processes as in axon 
guiding are happening. A group of secreted axon guid-
ance molecules, involved in neuronal development, has 
already been discussed and proven to be overexpressed 
in various carcinomas, as well as melanoma. It was also 
shown that the expression was correlated with advanced 
stage and grade of cancer [62]. Since the involvement 
of neuronal axon guiding factors in metastasis has been 
demonstrated by previous studies [63], it can be hypoth-
esized, that a reinforced neuronal profile may be a sign 
of increased migration and resistance to MAPKi of brain 
metastases, making neuronal proteins a potential target 
for future therapeutic approaches.
Demonstrated by the heterogeneity in therapeutic 
resistance, the plasticity of melanoma cells might allow 
the tumor to adapt to biological processes, for exam-
ple by EMT-like mechanisms. There are various spe-
cific molecular events associated with EMT, such as 
increased production of ECM components, activation of 
transcription factors and reorganization and expression 
of cytoskeletal proteins [21, 28]. EMT is also associated 
with induction of resistance and metastasis [26, 28, 29]. 
Fig. 4 Protein panel displays differences between poor and good responders. For each of the 9 most class-discriminating proteins (listed in Table 3), 
label-free quantification (LFQ) intensities in a logarithmic scale to the basis 2 are indicated. LFQ intensities for proteins not detected in a replicate 
were replaced by 15
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Fig. 5 Primary melanoma cell cultures derived from cerebral metastases. Stratification of the samples by proliferation and viability assay and calcu-
lation of the IC50 for BRAF/MEK inhibitors (a). Sensitive cells show E-cadherin positivity and N-cadherin negativity in immunocytochemistry (b) and 
Western blot (c), whereas resistant cells show E-cadherin negativity and N-cadherin positivity
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Especially, the down-regulation of E-cadherin is balanced 
by the increased expression of mesenchymal neural 
cadherin (N-cadherin). This, so called cadherin switch, 
alters cell adhesion [26, 27] and is considered to be a 
fundamental event in EMT, leading to a loss of cell–cell 
contact, increased invasive properties and typical mor-
phological changes [21, 28, 29]. EMT is associated with 
an induction of the mesenchymal marker N-cadherin or 
Cadherin-2 (CDH2), which we have shown to be signifi-
cantly up-regulated in poor responders. The biological 
reason behind the changes to a mesenchymal phenotype 
is the increased capability to detach from the epithelial 
layer and to gain the ability for migration [28].
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Fig. 6 Intensities from the targeted MS approach for 8 of the 9 proteins from the discriminative signature listed in Table 3. Statistics for this plot 
were done in MSstats (*p value < 0.05, **p value < 0.01, ***p value < 0.001)
Fig. 7 Functional annotation categories calculated in DAVID (DAVID Bioinformatics Resources 6.7, National Institute of Allergy and Infectious Dis-
eases) of correlating genes upregulated by TGFβ (EMT genes) to proteins up-regulated in brain metastasis of melanoma patients treated with BRAF 
and MEK inhibitors (see Additional file 4: Table S2 for full list of overlapping data between TGFβ induced signature in Microarray data and shotgun 
proteomics data in cerebral melanoma metastases). Fold enrichment values, count (genes involved in the term), p value and FDR (false discovery 
rate, calculated using the Benjamini–Hochberg procedure), listed next to the graph, were calculated using DAVID bioinformatics resources
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Fig. 8 Kaplan-meier plots visualizing the survival of patients for DDB1- and CUL4-associated factor 7 (a), Ubiquitin-conjugating enzyme E2 Q1 (b) 
and Anamorsin (c) based on The Cancer Genome Atlas dataset (TCGA, cutaneous melanoma dataset (n = 456))
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The concept of phenotype switching, first described in 
melanoma by Hoek et al. [19, 20], characterizes two tran-
scriptional distinct melanoma cell populations, a prolif-
erative and an invasive type. The phenotype-switching 
model accounts for disease progression and tumor het-
erogeneity, as well as aspects of resistance [22]. Mela-
noma cells are able to switch back and forth between 
these two phenotypes [21]. Also, melanoma cells have 
shown to change their phenotype from proliferative to 
invasive state in response to targeted therapy with BRAFi 
and MEKi, which is associated with drug resistance. 
Furthermore, proliferative melanoma cells have been 
shown to be more responsive to MAPK pathway inhi-
bition than invasive phenotype cells, independently of 
their mutation status [23, 24]. The major role in pheno-
type switching and the transition from a proliferative to 
an invasive cell type and ultimately leading to metastasis 
is related to EMT-like mechanisms [25]. Identifying criti-
cal switches in EMT processes and finding a way to block 
these, might serve as a strategy to prevent metastasis and 
to decrease therapeutic resistance. The presently charac-
terized mechanisms might thus not only provide insight 
into mechanisms of resistance but may also increase the 
understanding of the metastasis processes. In this pilot 
study, we were able to detect EMT features, as well as an 
increase of proteins involved in calcium ion binding and 
cell adhesion in line with previous published data [53]. 
Interaction with the ECM is also important for metas-
tasis, since cells need to be able to adhere. A recently 
published study also exhibited a higher capability of cell 
adherence demonstrating that Vemurafenib resistant 
cells undergoing EMT have an increased ability to inter-
act with ECM proteins [64].
Possible potential lies in the identified groups of 
exchanger and transporter proteins (Table  1), which we 
detected an over-representation in the poor responder 
patient group. There are candidates among the trans-
porter proteins, which are not only involved in leukocyte 
migration but also in many transport processes. It can 
therefore be hypothesized that these transport activi-
ties also take place in drug efflux, leading or contributing 
to therapy resistance. Enhanced drug efflux membrane 
transporters has already been described in chemoresist-
ance [65]. Na+/H+ exchangers or antiporters have been 
associated with cancer metastasis and invasion [66–69], 
making them valuable for future drug development [70].
Patients who responded well to MAPKi treatment 
revealed a huge number of significantly up-regulated 
immune response related proteins such as myeloperoxi-
dase (MPO), HLA proteins and immunoglobulin chains. 
Although these patients were not treated with immuno-
therapy, the immune system is always involved in cancer 
defense. This leads to the presumption that in patients 
who showed good response to therapy, melanoma is bet-
ter recognizable for the immune system via these up-reg-
ulated receptors and fragments. It also has recently been 
shown that many subtypes of HLA molecules are down-
regulated during MAPKi resistance [71], supporting the 
good response of patients with up-regulated HLA pro-
teins. MPO is a peroxidase enzyme expressed in profes-
sional phagocytic cells, most abundantly in neutrophils. 
It is involved in cellular homeostasis and of particular 
interest because of its important role in the initiation and 
progression of acute and chronic inflammatory diseases 
[72]. Although in some cases of neoplastic malignancies 
there is research pointing out the actively tumor promot-
ing function of immune inflammatory cells [60], there 
a b
Fig. 9 Immunohistochemistry of FFPE cerebral melanoma metastases cohort (n = 22). Evaluation of good responders (n = 7) versus poor respond-
ers (n = 15) shows significant different expression of he T cell marker CD3 (orange; p value = 0.002), CD4 (green; p value = 0.025) and CD8 (blue; p 
value = 0.007) visualized in the scatter plot (a) and by examples of the staining results (b)
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are also mechanisms known by which adaptive immune 
cells modulate cancer for example by cytokine-mediated 
lysis of tumor cells [73]. ECM structural constituents, 
as well as proteins involved in cell adhesion were sig-
nificantly up-regulated amongst patients who showed a 
good response to therapy. Compared to poor responders, 
in this case the cell adhesion molecules are involved in 
immune response, leukocyte migration and ECM organ-
ization. This accounts for the activation of the immune 
system and may be due to the organism attacking the 
metastases. Apolipoproteins might be another interest-
ing group for further investigation. In patients with good 
treatment response they were significantly up-regulated 
and have already been described as a probable prognostic 
factor and can be predictive for survival [74].
Finally, we wanted to be able to differentiate between 
good and poor responding patients and translate our 
data towards clinical application. To identify a poten-
tial biomarker profile, we constructed a classifier based 
on nearest shrunken centroids. We identified 9 proteins 
that are necessary to discriminate between good and 
poor responding patients, namely Glutathione S-trans-
ferase Mu 3, DDB1- and CUL4-associated factor 7, 
Peptidyl-prolyl cis–trans isomerase A, Anamorsin, Dehy-
drogenase/reductase SDR family member 11, Ubiquitin-
conjugating enzyme E2 Q1, NudC domain-containing 
protein 3, Prostaglandin reductase 3 and V-type proton 
ATPase subunit F (Fig.  4). Literature research demon-
strated that these candidates are involved in resistance or 
tumor progression and exert novelty in the field of mela-
noma resistance (Table 3).
With the targeted approach we were successfully able 
to validate 8 out of the 9 proteins.
We also made use of the TCGA database, which pro-
vides clinical information and gene expression of 456 
melanoma samples. Here we were able to correlate 
DDB1- and CUL4-associated factor 7 (DCAF7), Ubiqui-
tin-conjugating enzyme E2 Q1 (UBE2Q1) and Anamor-
sin (CIAPIN1) also on gene expression level with poor 
survival, demonstrating clinical relevance of the protein 
signature.
As previously described EMT plays a crucial role in 
metastasis. By inducing EMT in a cell culture melanoma 
model with previous sensitivity, we detected the typical 
signature also identified in the poor responding patients. 
This fortifies EMT as a major classifier between good 
and poor prognosis. We could validate the observation 
that EMT is an important process in resistance in brain 
metastases of melanoma by staining on the main factors 
involved in EMT (E- and N-cadherin) by immunocyto-
chemistry and Western blotting.
High amounts of tumor-infiltrating lymphocytes 
(TILs), high ratios of PD-1+/CD8+ cells and high levels 
of PD-L1 were shown to be negatively correlated with 
brain metastases size, although there was no significant 
association of patient survival with TILs [75]. Another 
study showed that T-cell specific genes such as CD3 
and CD8 are expressed at higher levels in patients with 
a prolonged overall survival [76]. Meaning any molecule 
associated with the presence of T cells implies a better 
outcome, which is consistent with the published litera-
ture about the association of TILs with good prognosis. 
Concerning TILs, CD3+ and CD8+ T cells may be the 
most important effector population during regression of 
melanoma metastasis [77]. T cell infiltrated melanomas, 
especially those with high CD8+ cells, are more likely 
to be associated with PD-L1 expression in tumor cells, 
an increased prognosis and increased time to develop 
brain metastasis [78]. With our FFPE cohort we were 
able to demonstrate that poor response is characterized 
by a lower infiltrate of immune cells in melanoma brain 
metastases confirming our observation of the over-repre-
sentation of immunogenic marker in the good responder. 
This is in line with recent literature and gives new 
insights into MAPKi resistance and brain metastases. 
This leads us to the assumption that also MAPKi resist-
ant patients could benefit from immunotherapy-induced 
activation of their immune system, since we see higher 
immune infiltration in tumors of patients that responded 
well to therapy.
Conclusions
Drug resistance mechanisms are content of latest 
research. Calcium ion binding proteins, EIFs, EMT, lyso-
somal pathway and others have already been identified by 
previous proteome analyses as main features associated 
with resistance. With our tissue proteomic approach, 
we were able to detect similar resistance mechanisms in 
cerebral metastases, indicating resemblance to visceral 
metastases. The cerebral metastases of poorly responding 
patients expressed transporter and exchanger proteins in 
a higher amount, which might, especially in the brain, be 
responsible for drug efflux and thus contribute to therapy 
resistance. With patients who showed good response to 
therapy the immunogenic signature indicates a better 
response to targeted therapy combined with immuno-
therapy. This suggests that patients with a poor response 
to MAPKi might also benefit from activating their 
immune system. Further studies analyzing the function of 
these targets are warranted. Evaluation of new treatment 
options in vitro is necessary to verify possible candidates. 
Additional studies with increased sample size will also 
give more profound insights into the pathomechanisms 
of MAPKi resistance. Intensive research is demanded for 
the detection of promising therapeutics and to under-
stand resistance mechanisms. Primary tumors collected 
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today are from huge relevance, not only for research but 
also for the patient. The availability of adequate sample 
material for future studies will determine the validity of 
the gained evidence. By initiating appropriate biobank 
approaches, future scientific endeavors to develop novel 
therapies or stratification of patients for better treatment 
can be ensured [79].
Abbreviations
ACN: acetonitrile; Acc. Nr.: accession number; BP: biological process; BSA: 
bovine serum albumin; CC: cellular component; DTT: dithiothreitol; ECM: 
extracellular matrix; EIF: eukaryotic translation initiation factor; EMT: epithelial 
to mesenchymal transition; FA: formic acid; FBS: fetal bovine serum; FDR: false 
discovery rate; FFPE: formalin-fixed paraffin-embedded; GO: gene ontol-
ogy; GSEA: gene set enrichment analysis; HCD: higher-energy collisional 
dissociation; HLA: human leukocyte antigen; IAA: iodoacetamide; KEGG: 
Kyoto Encyclopedia of Genes and Genomes; LFQ: label-free quantification; Ig: 
immunoglobulin; MAPK: mitogen-activated protein kinase; MEK: mitogen-
activated protein kinase; MF: molecular function; MPO: myeloperoxidase; 
MWCO: molecular weight cut-off; PBS: phosphate buffered saline; PFS: 
progression-free survival; ppm: parts per million; SDS-PAGE: sodium dodecyl 
sulfate polyacrylamide gel electrophoresis; TCGA: The Cancer Genome Atlas; 
TFA: trifluoroacetic acid; TILs: tumor-infiltrating lymphocytes.
Authors’ contributions
VP designed, coordinated and supervised the study, performed selection of 
the clinical samples and analyzed the major part of the proteome and micro-
array data and interpreted all data. NZ performed LC–MS sample preparation, 
cell culture experiments and data analysis. AB and CG performed shotgun 
LC–MS/MS analysis. BM, LJ and CG performed targeted LC–MS/MS analysis. AB 
supported NZ with the sample preparation for the shotgun LC–MS approach 
and supported VP and NZ with data analysis. LJ supported NZ with the sample 
preparation for the targeted LC–MS approach. BM, LJ and CG supported NZ 
with the data analysis of the targeted LC–MS/MS analysis. OME performed 
TGFβ treatment of melanoma cell lines and Microarray analysis. PFC analyzed 
the TCGA data. RD and MPL were responsible for biobanking and sample 
collection. The biobank team of MPL performed mutational analysis of the 
samples. NZ drafted the article. All authors provided critical review of the 
manuscript and approved the submission. All authors read and approved the 
final manuscript.
Additional files
Additional file 1: Figure S1. Study outline shows the experimental 
design of the study.
Additional file 2: Table S1. Clinical table with age, gender, treatment, 
response distribution, PFS, mutational status, all number of samples, IC50 
of the cell systems and the applied methods.
Additional file 3: Figure S2. Complement and coagulation cascades (A) 
are enriched in good responder. Cell adhesion molecules (B), calcium sign-
aling pathway (C) and MAPK signaling pathway (D) are highly enriched 
and up-regulated in poor responder, as visualized by GSEA.
Additional file 4: Table S2. Statistical output for GSEA (gene set enrich-
ment analysis). Nominal p-value, false discovery rate (FDR) and familywise-
error rate (FWER) are given for the for significantly enriched protein sets.
Additional file 5: Figure S3. Correlation of proteins (P62937, P61962, 
Q6FI81, P21266) identified by nearest shrunken centroid and CPL/MUW 
proteome database, including 255 cell cultures, cell states and tissue, lead-
ing to a high protein similarity to the resistant melanoma cell line TMFI.
Additional file 6: Table S3. Genes upregulated in melanoma cells by 
TGFβ signaling correlating with proteins that were also found to be upreg-
ulated in the cerebral melanoma metastases by proteomics.
Author details
1 Department of Dermatology, Medical University of Vienna, Waehringer Guer-
tel 18–20, 1090 Vienna, Austria. 2 Department of Analytical Chemistry, Faculty 
of Chemistry, University of Vienna, Vienna, Austria. 3 University of Applied 
Sciences (FH Campus Wien), Vienna, Austria. 4 Department of Dermatology, 
University of Zurich, University Hospital Zurich, Zurich, Switzerland. 
Acknowledgements
The biobank team is highly acknowledged: Alice Langer, Agathe Duda, Daniel 
Hug, Ines Kleiber-Schaaf, Mirka Schmid and Tabea Koch. We would also like 
to thank the Mass Spectrometry Center (MSC) of the Chemical Faculty of the 
University of Vienna for support. Further we want to thank Tina Holper, Ulrike 
Mann and Barbara Sterniczky for excellent technical support in times when it 
was needed.
Competing interests
The authors declare that they have no competing interests.
Availability of data and material
The mass spectrometry proteomics data have been deposited to the Pro-
teomeXchange Consortium via the PRIDE partner repository with the dataset 
identifier PXD007592 and https://doi.org/10.6019/pxd007592.
Consent for publication
Not applicable.
Ethics approval and consent to participate
All Samples were collected from the Biobank of the Dermatology Department 
at the University Hospital Zurich, with the approval by the ethics committee 
and informed consent obtained from patients, all experiments were carried 
out according to the Declaration of Helsinki principles.
Funding
This study was supported by the following grants: Promedica (VP), MUW 
mobility (VP), URPP Translational Cancer Research (RD, VP) and Louis Widmer 
(VP).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 30 August 2017   Accepted: 2 March 2018
References
 1. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, 
et al. Malignant melanoma in the 21st century, part 1: epidemiol-
ogy, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 
2007;82:364–80.
 2. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, et al. 
Malignant melanoma in the 21st century, part 2: staging, prognosis, and 
treatment. Mayo Clin Proc. 2007;82:490–513.
 3. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. 
Incidence proportions of brain metastases in patients diagnosed (1973 
to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin 
Oncol. 2004;22:2865–72.
 4. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain 
metastases in a cohort of patients with carcinoma of the breast, colon, 
kidney, and lung and melanoma. Cancer. 2002;94:2698–705.
 5. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu W-J, et al. 
Prognostic factors for survival in melanoma patients with brain metasta-
ses. Cancer US. 2011;117:1687–96.
 6. Sampson JH, Carter JHJ, Friedman AH, Seigler HF. Demographics, prog-
nosis, and therapy in 702 patients with brain metastases from malignant 
melanoma. J Neurosurg. 1998;88:11–20.
 7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations 
of the BRAF gene in human cancer. Nature. 2002;417:949–54.
Page 21 of 22Zila et al. Clin Proteom  (2018) 15:13 
 8. Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining 
targeted therapy and immune checkpoint inhibitors in the treatment of 
metastatic melanoma. Cancer Biol Med. 2014;11:237–46.
 9. Lin NU. Targeted therapies in brain metastases. Curr Treat Options Neurol. 
2014;16:276.
 10. Gorantla V, Kirkwood JM, Tawbi HA. Melanoma brain metastases: 
an unmet challenge in the era of active therapy. Curr Oncol Rep. 
2013;15:483–91.
 11. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell 
L, et al. Vemurafenib in patients with BRAF(V600) mutation-positive mela-
noma with symptomatic brain metastases: final results of an open-label 
pilot study. Eur J Cancer Engl. 2014;50:611–21.
 12. Arance AM, Berrocal A, Lopez-Martin JA, de la Cruz-Merino L, Soriano V, 
Martin Algarra S, et al. Safety of vemurafenib in patients with BRAF V600 
mutated metastatic melanoma: the Spanish experience. Oncol: Clin 
Transl; 2016.
 13. Spagnolo F, Picasso V, Lambertini M, Ottaviano V, Dozin B, Queirolo P. 
Survival of patients with metastatic melanoma and brain metastases in 
the era of MAP-kinase inhibitors and immunologic checkpoint blockade 
antibodies: a systematic review. Cancer Treat Rev. 2016;45:38–45.
 14. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dis-
secting therapeutic resistance to RAF inhibition in melanoma by tumor 
genomic profiling. J Clin Oncol US. 2011;29:3085–96.
 15. Mcarthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, 
et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600 K 
mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, 
randomised, open-label study. Lancet Oncol. 2014;15:323–32.
 16. Spagnolo F, Ghiorzo P, Orgiano L, Pastorino L, Picasso V, Tornari E, et al. 
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, 
and diagnostic strategies. Onco Targets Ther. 2015;8:157–68.
 17. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Com-
bined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl 
J Med. 2014;371:1867–76.
 18. Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mack-
iewicz A, et al. Comparison of dabrafenib and trametinib combination 
therapy with vemurafenib monotherapy on health-related quality of life 
in patients with unresectable or metastatic cutaneous BRAF Val600-muta-
tion-positive melanoma (COMBI-v): results of a phase 3, open-l. Lancet 
Oncol Engl. 2015;16:1389–98.
 19. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, et al. 
Metastatic potential of melanomas defined by specific gene expression 
profiles with no BRAF signature. Pigment Cell Res. 2006;19:290–302.
 20. Hoek KS, Eichhoff OM, Schlegel NC, Dobbeling U, Kobert N, Schaerer L, 
et al. In vivo switching of human melanoma cells between proliferative 
and invasive states. Cancer Res. 2008;68:650–6.
 21. Paulitschke V, Eichhoff O, Cheng PF, Levesque MP, Höller C. Proteomics 
approaches to understanding mitogen-activated protein kinase inhibitor 
resistance in melanoma. Curr Opin Oncol. 2016;28:172–9.
 22. Widmer DS, Eichhoff OM, Dummer R, Levesque MP. Melanoma’s next top 
model, it is in the air. Exp Dermatol. 2015;24:659–60.
 23. Eichhoff OM, Zipser MC, Xu M, Weeraratna AT, Mihic D, Dummer R, et al. 
The immunohistochemistry of invasive and proliferative phenotype 
switching in melanoma: a case report. Melanoma Res. 2010;20:349–55.
 24. Zipser MC, Eichhoff OM, Widmer DS, Schlegel NC, Schoenewolf NL, 
Stuart D, et al. A proliferative melanoma cell phenotype is responsive to 
RAF/MEK inhibition independent of BRAF mutation status. Pigment Cell 
Melanoma Res. 2011;24:326–33.
 25. Schlegel NC, von Planta A, Widmer DS, Dummer R, Christofori G. PI3 K sig-
nalling is required for a TGFβ-induced epithelial-mesenchymal-like transi-
tion (EMT-like) in human melanoma cells. Exp Dermatol. 2015;24:22–8.
 26. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. 
Cancer Metastasis Rev. 2009;28:15–33.
 27. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin 
switching. J Cell Sci. 2008;121:727–35.
 28. Kalluri R, Weinberg RA. Review series. The basics of epithelial-mesenchy-
mal transition. J Clin Invest. 2009;119:1420–8.
 29. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial–mesenchymal 
transitions in development and disease. Cell. 2009;139:871–90.
 30. Wimmer H, Gundacker NC, Griss J, Haudek VJ, Stattner S, Mohr T, et al. 
Introducing the CPL/MUW proteome database: interpretation of human 
liver and liver cancer proteome profiles by referring to isolated primary 
cells. Electrophor Ger. 2009;30:2076–89.
 31. Bradford MM. A rapid and sensitive method for the quantitation of micro-
gram quantities of protein utilizing the principle of protein-dye binding. 
Anal Biochem. 1976;72:248–54.
 32. Wisniewski JR, Zougman A, Nagaraj N, Mann M, Wi JR. Universal sample 
preparation method for proteome analysis. Nat Methods. 2009;6:377–62. 
http://www.ncbi.nlm.nih.gov/pubmed/19377485.
 33. Bileck A, Kreutz D, Muqaku B, Slany A, Gerner C. Comprehensive assess-
ment of proteins regulated by dexamethasone reveals novel effects in 
primary human peripheral blood mononuclear cells. J Proteome Res. 
2014;13:5989–6000.
 34. Slany A, Bileck A, Kreutz D, Mayer RL, Muqaku B, Gerner C. Contribu-
tion of human fibroblasts and endothelial cells to the Hallmarks of 
Inflammation as determined by proteome profiling. Mol Cell Proteom. 
2016;15(6):1982–97.
 35. Cox J, Mann M. MaxQuant enables high peptide identification rates, 
individualized p.p.b.-range mass accuracies and proteome-wide protein 
quantification. Nat Biotechnol. 2008;26:1367–72.
 36. Cox J, Mann M. 1D and 2D annotation enrichment: a statistical method 
integrating quantitative proteomics with complementary high-through-
put data. BMC Bioinform. 2012;13:S12.
 37. Vizcaíno JA, Csordas A, Del-Toro N, Dianes JA, Griss J, Lavidas I, et al. 2016 
update of the PRIDE database and its related tools. Nucleic Acids Res. 
2016;44:D447–56.
 38. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: 
paths toward the comprehensive functional analysis of large gene lists. 
Nucleic Acids Res Engl. 2009;37:1–13.
 39. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis 
of large gene lists using DAVID bioinformatics resources. Nat Protoc Engl. 
2009;4:44–57.
 40. Geiger T, Cox J, Mann M. Proteomic changes resulting from gene copy 
number variations in cancer cells. PLoS Genet. 2010;6:e1001090.
 41. Luo W, Brouwer C. Pathview: an R/Bioconductor package for pathway-
based data integration and visualization. Bioinformatics. 2013;29:1830–1.
 42. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gil-
lette MA, et al. Gene set enrichment analysis: a knowledge-based 
approach for interpreting genome-wide expression profiles. Proc 
Natl Acad Sci USA. 2005;102:15545–50. http://www.ncbi.nlm.nih.gov/
pubmed/16199517%0Ahttp://www.pubmedcentral.nih.gov/articleren-
der.fcgi?artid=PMC1239896.
 43. Dabney AR. ClaNC: point-and-click software for classifying microarrays to 
nearest centroids. Bioinformatics. 2006;22:122–3.
 44. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, 
et al. Skyline: an open source document editor for creating and analyzing 
targeted proteomics experiments. Bioinformatics. 2010;26:966–8.
 45. Muqaku B, Eisinger M, Meier SM, Tahir A, Pukrop T, Haferkamp S, et al. 
Multi-omics analysis of serum samples demonstrates reprogramming of 
organ functions via systemic calcium mobilization and platelet activation 
in metastatic melanoma. Mol Cell Proteom. 2017;16:86–99. http://www.
mcponline.org/lookup/doi/10.1074/mcp.M116.063313.
 46. Choi M, Chang C-Y, Clough T, Broudy D, Killeen T, MacLean B, et al. 
MSstats: an R package for statistical analysis of quantitative mass spec-
trometry-based proteomic experiments. Bioinformatics. 2014;30:2524–6. 
https://academic.oup.com/bioinformatics/bioinformatics/
article/2748156/MSstats.
 47. Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, et al. 
Modeling genomic diversity and tumor dependency in malignant mela-
noma. Cancer Res. 2008;68:664–73.
 48. Eichhoff OM, Weeraratna A, Zipser MC, Denat L, Widmer DS, Xu M, et al. 
Differential LEF1 and TCF4 expression is involved in melanoma cell phe-
notype switching. Pigment Cell Melanoma Res. 2011;24:631–42.
 49. Widmer DS, Cheng PF, Eichhoff OM, Belloni BC, Zipser MC, Schlegel NC, 
et al. Systematic classification of melanoma cells by phenotype-specific 
gene expression mapping. Pigment Cell Melanoma Res. 2012;25:343–53.
 50. Cheng PF, Shakhova O, Widmer DS, Eichhoff OM, Zingg D, Frommel SC, 
et al. Methylation-dependent SOX9 expression mediates invasion in 
human melanoma cells and is a negative prognostic factor in advanced 
melanoma. Genome Biol. 2015;16:42.
Page 22 of 22Zila et al. Clin Proteom  (2018) 15:13 
 51. TCGA. Genomic classification of cutaneous melanoma. Cell. 
2015;161:1681–96. http://linkinghub.elsevier.com/retrieve/pii/
S0092867415006340.
 52. Domon B, Aebersold R. Options and considerations when selecting a 
quantitative proteomics strategy. Nat Biotechnol. 2010;28:710–21.
 53. Paulitschke V, Haudek-Prinz V, Griss J, Berger W, Mohr T, Pehamberger H, 
et al. Functional classification of cellular proteome profiles support the 
identification of drug resistance signatures in melanoma cells. J Proteome 
Res. 2013;12:3264–76.
 54. Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow 
B, et al. Dependency of a therapy-resistant state of cancer cells on a lipid 
peroxidase pathway. Nature. 2017;547:453–7.
 55. Ascierto PA, Kirkwood JM, Grob J-J, Simeone E, Grimaldi AM, Maio M, et al. 
The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.
 56. Conboy IM, Manoli D, Mhaiskar V, Jones PP. Calcineurin and vacuolar-type 
H+-ATPase modulate macrophage effector functions. Proc Natl Acad Sci 
USA. 1999;96:6324–9.
 57. Sun-Wada GH, Wada Y. Vacuolar-type proton pump ATPases: acidification 
and pathological relationships. Histol Histopathol. 2013;28:805–15.
 58. Daniel C, Bell C, Burton C, Harguindey S, Reshkin SJ, Rauch C. The role of 
proton dynamics in the development and maintenance of multidrug 
resistance in cancer. Biochim Biophys Acta. 2013;1832:606–17.
 59. Spilka R, Ernst C, Mehta AK, Haybaeck J. Eukaryotic translation initiation 
factors in cancer development and progression. Cancer Lett Ireland. 
2013;340:9–21.
 60. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 
2011;144:646–74.
 61. Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, 
Tomasic G, et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK 
cancer therapies. Nature. 2014;513:105–9.
 62. Wu F, Zhou Q, Yang J, Duan GJ, Ou JJ, Zhang R, et al. Endogenous axon 
guiding chemorepulsant semaphorin-3F inhibits the growth and metas-
tasis of colorectal carcinoma. Clin Cancer Res. 2011;17:2702–11.
 63. Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour 
progression and tumour angiogenesis. Nat Rev Cancer. 2008;8:632–45.
 64. Paulitschke V, Berger W, Paulitschke P, Hofstatter E, Knapp B, Dingelmaier-
Hovorka R, et al. Vemurafenib resistance signature by proteome analysis 
offers new strategies and rational therapeutic concepts. Mol Cancer Ther. 
2015;14:757–68.
 65. Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, et al. Overcoming ABC 
transporter-mediated multidrug resistance: molecular mechanisms and 
novel therapeutic drug strategies. Drug Resist. Updates. 2016;27:14–29.
 66. Stock C, Schwab A. Protons make tumor cells move like clockwork. 
Pflugers Arch Eur J Physiol. 2009;458:981–92.
 67. Loo SY, Chang MKX, Chua CSH, Kumar AP, Pervaiz S, Clement MV. NHE-1: 
a promising target for novel anti-cancer therapeutics. Curr Pharm Des. 
2012;18:1372–82.
 68. Amith SR, Fliegel L. Regulation of the Na+/H+ exchanger (NHE1) in 
breast cancer metastasis. Cancer Res. 2013;73:1259–64.
 69. Reshkin SJ, Greco MR, Cardone RA. Role of pHi, and proton transporters 
in oncogene-driven neoplastic transformation. Philos Trans R Soc Lond B 
Biol Sci. 2014;369:20130100.
 70. Jinadasa T, Josephson CB, Boucher A, Orlowski J. Determinants of cation 
permeation and drug sensitivity in predicted transmembrane helix 9 and 
adjoining exofacial re-entrant loop 5 of Na(+)/H(+) exchanger NHE1. J 
Biol Chem. 2015;290:18173–86.
 71. Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, et al. Non-genomic and 
immune evolution of melanoma acquiring MAPKi resistance. Cell. 
2015;162:1271–85.
 72. Olza J, Aguilera CM, Gil-Campos M, Leis R, Bueno G, Martinez-Jimenez 
MD, et al. Myeloperoxidase is an early biomarker of inflammation and 
cardiovascular risk in prepubertal obese children. Diabetes Care US. 
2012;35:2373–6.
 73. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune 
system during cancer development. Nat Rev Cancer. 2006;6:24–37.
 74. Labots M, Schütte LM, van der Mijn JC, Pham TV, Jiménez CR, Verheul 
HMW. Mass spectrometry-based serum and plasma peptidome profiling 
for prediction of treatment outcome in patients with solid malignancies. 
Oncologist. 2014;19:1028–39.
 75. Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, et al. Distribu-
tion and prognostic relevance of tumor-infiltrating lymphocytes (TILs) 
and PD-1/PD-L1 immune checkpoints in human brain metastases. 
Oncotarget. 2015;6:40836–49. http://www.oncotarget.com/fulltext/5696.
 76. Krahenbuhl L, Goldinger SM, Mangana J, Kerl K, Chevolet I, Brochez 
L, et al. A longitudinal analysis of IDO and PDL1 expression during 
immune- or targeted therapy in advanced melanoma. Neoplasia US. 
2018;20:218–25.
 77. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, et al. 
Liver metastasis and treatment outcome with anti-PD-1 monoclonal 
antibody in patients with melanoma and NSCLC. Cancer Immunol 
Res. 2017;5:417–24. http://cancerimmunolres.aacrjournals.org/lookup/
doi/10.1158/2326-6066.CIR-16-0325.
 78. Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VLS, Sznol M, et al. 
Characterization of PD-L1 expression and associated T-cell infiltrates in 
metastatic melanoma samples from variable anatomic sites. Clin Cancer 
Res. 2015;21:3052–60.
 79. Dummer R, Goldinger SM, Paulitschke V, Levesque MP. Curing advanced 
melanoma by 2025. Curr Opin Oncol. 2015;27:125–7.
 80. Glutathione S-transferase Mu 3. UniProt knowledgebase. http://www.
uniprot.org/uniprot/P21266. Accessed 13 Oct 2017.
 81. Hosono N, Kishi S, Iho S, Urasaki Y, Yoshida A, Kurooka H, et al. Glu-
tathione S-transferase M1 inhibits dexamethasone-induced apoptosis in 
association with the suppression of Bim through dual mechanisms in a 
lymphoblastic leukemia cell line. Cancer Sci. 2010;101:767–73.
 82. DDB1- and CUL4-associated factor 7. UniProt Knowledgebase. http://
www.uniprot.org/uniprot/P61962. Accessed 13 Oct 2017.
 83. DCAF7 DDB1 and CUL4 associated factor 7 [Homo sapiens (human)]. 
NCBI Gene [Internet]. Available from https://www.ncbi.nlm.nih.gov/
gene/10238. Accessed 13 Oct 2017.
 84. Fujioka H, Sakai A, Tanaka S, Kimura K, Miyamoto A, Iwamoto M, et al. 
Comparative proteomic analysis of paclitaxel resistance-related proteins 
in human breast cancer cell lines. Oncol Lett. 2017;13:289–95.
 85. Peptidyl-prolyl cis-trans isomerase A. UniProt knowledgebase. http://
www.uniprot.org/uniprot/P62937. Accessed 13 Oct 2017.
 86. V-type proton ATPase subunit F. UniProt Knowledgebase. http://www.
uniprot.org/uniprot/Q16864. Accessed 13 Oct 2017.
 87. Anamorsin. UniProt knowledgebase. http://www.uniprot.org/uniprot/
Q6FI81. Accessed 13 Oct 2017.
 88. Lu D, Xiao Z, Wang W, Xu Y, Gao S, Deng L, et al. Down regulation of 
CIAPIN1 reverses multidrug resistance in human breast cancer cells by 
inhibiting MDR1. Molecules. 2012;17:7595–611.
 89. Dehydrogenase/reductase SDR family member 11. UniProt knowledge-
base. http://www.uniprot.org/uniprot/Q6UWP2. Accessed 13 Oct 2017.
 90. Endo S, Miyagi N, Matsunaga T, Hara A, Ikari A. Human dehydrogenase/
reductase (SDR family) member 11 is a novel type of 17β-hydroxysteroid 
dehydrogenase. Biochem Biophys Res Commun. 2016;472:231–6.
 91. Ubiquitin-conjugating enzyme E2 Q1. UniProt knowledgebase. http://
www.uniprot.org/uniprot/Q7Z7E8. Accessed 13 Oct 2017.
 92. Fahmidehkar MA, Shafiee SM, Eftekhar E, Mahbudi L, Seghatoleslam A. 
Induction of cell proliferation, clonogenicity and cell accumulation in S 
phase as a consequence of human UBE2Q1 overexpression. Oncol Lett. 
2016;12:2169–74.
 93. NudC domain-containing protein 3. UniProt knowledgebase. http://
www.uniprot.org/uniprot/Q8IVD9. Accessed 13 Oct 2017.
 94. NUDCD3 NudC domain containing 3 [Homo sapiens (human)]. NCBI 
Gene. https://www.ncbi.nlm.nih.gov/gene/23386. Accessed 16 Oct 2017.
 95. Prostaglandin reductase 3. UniProt knowledgebase. http://www.uniprot.
org/uniprot/Q8N4Q0. Accessed 13 Oct 2017.
 96. Xue L, Zhu Z, Wang Z, Li H, Zhang P, Wang Z, et al. Knockdown of prosta-
glandin reductase 1 (PTGR1) suppresses prostate cancer cell proliferation 
by inducing cell cycle arrest and apoptosis. Biosci Trends. 2016;10:133–9.
